Oasmia Pharmaceutical AB develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company's approved products include Paclical/Apealea for the treatment of ovarian and metastatic breast cancer; and Doxophos for the treatment of various doxorubicin indications. It also develops Docecal for breast cancer; OAS-19 and KB9520 for various cancers; Paccal Vet for mammary carcinoma and squamous cell carcinoma; and Doxophos Vet for lymphoma. Oasmia Pharmaceutical AB was founded in 1988 and is based in Uppsala, Sweden.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/15/2019 11:46 PDT] Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM), Down By 100.00% ($1.87) From $1.870 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [05/07/2019 07:35 PDT] OASM Expected to Trade Up After Bullish Patterns Develop
• [04/30/2019 07:51 PDT] OASM Expected to Trade Down After Bearish Patterns Develop
• [04/26/2019 10:30 PDT] Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM), Down By 100.00% ($2.19) From $2.190 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [04/17/2019 07:49 PDT] OASM Expected to Trade Down After Bearish Patterns Develop
• [03/27/2019 07:54 PDT] OASM Expected to Trade Up After Bullish Patterns Develop
• [03/26/2019 07:52 PDT] OASM Expected to Trade Down After Bearish Patterns Develop